Tags

Type your tag names separated by a space and hit enter

Emerging therapeutic approaches for multipotent mesenchymal stromal cells.
Curr Opin Hematol. 2010 Nov; 17(6):505-13.CO

Abstract

PURPOSE OF REVIEW

Multipotent mesenchymal stromal cells (MSCs) are rare cells resident in bone marrow and other organs capable of differentiating into mesodermal lineage tissues. MSCs possess immunomodulatory properties and have extensive capacity for ex-vivo expansion. Early clinical studies demonstrated safety and feasibility of infusing autologous MSCs and suggested a role in enhancing engraftment after hematopoietic cell transplant (HCT). Subsequent pilot studies using allogeneic MSCs showed safety but presented contradictory results regarding efficacy in treating graft-versus-host disease (GVHD).

RECENT FINDINGS

Larger, phase II allogeneic MSC infusion studies, including cells obtained from haploidentical and third-party donors, showed efficacy in GVHD treatment; however, recent randomized, placebo-controlled studies failed to corroborate these results. New investigations include MSC infusions in umbilical cord blood transplantation, MSC therapy for tissue regeneration/repair, harvest and use of MSCs from adipose tissue and cell-tracking/imaging studies using radionuclides, gene and fluorescent dye-labeled MSCs.

SUMMARY

MSCs remain the subject of intense investigation in HCT because of their differentiation potential and immunomodulatory properties. Whereas infusions of autologous, allogeneic and third-party donor MSCs are well tolerated, further research is needed to clarify the optimal methods for harvesting and expansion, optimal timing of administration and efficacy in the setting of HCT.

Authors+Show Affiliations

Department of Medicine, Case Western Reserve University, Case Comprehensive Cancer Center, University Hospitals Case Medical Center, Cleveland, Ohio 44106, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

20729733

Citation

Caimi, Paolo F., et al. "Emerging Therapeutic Approaches for Multipotent Mesenchymal Stromal Cells." Current Opinion in Hematology, vol. 17, no. 6, 2010, pp. 505-13.
Caimi PF, Reese J, Lee Z, et al. Emerging therapeutic approaches for multipotent mesenchymal stromal cells. Curr Opin Hematol. 2010;17(6):505-13.
Caimi, P. F., Reese, J., Lee, Z., & Lazarus, H. M. (2010). Emerging therapeutic approaches for multipotent mesenchymal stromal cells. Current Opinion in Hematology, 17(6), 505-13. https://doi.org/10.1097/MOH.0b013e32833e5b18
Caimi PF, et al. Emerging Therapeutic Approaches for Multipotent Mesenchymal Stromal Cells. Curr Opin Hematol. 2010;17(6):505-13. PubMed PMID: 20729733.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Emerging therapeutic approaches for multipotent mesenchymal stromal cells. AU - Caimi,Paolo F, AU - Reese,Jane, AU - Lee,Zhenghong, AU - Lazarus,Hillard M, PY - 2010/8/24/entrez PY - 2010/8/24/pubmed PY - 2011/2/23/medline SP - 505 EP - 13 JF - Current opinion in hematology JO - Curr. Opin. Hematol. VL - 17 IS - 6 N2 - PURPOSE OF REVIEW: Multipotent mesenchymal stromal cells (MSCs) are rare cells resident in bone marrow and other organs capable of differentiating into mesodermal lineage tissues. MSCs possess immunomodulatory properties and have extensive capacity for ex-vivo expansion. Early clinical studies demonstrated safety and feasibility of infusing autologous MSCs and suggested a role in enhancing engraftment after hematopoietic cell transplant (HCT). Subsequent pilot studies using allogeneic MSCs showed safety but presented contradictory results regarding efficacy in treating graft-versus-host disease (GVHD). RECENT FINDINGS: Larger, phase II allogeneic MSC infusion studies, including cells obtained from haploidentical and third-party donors, showed efficacy in GVHD treatment; however, recent randomized, placebo-controlled studies failed to corroborate these results. New investigations include MSC infusions in umbilical cord blood transplantation, MSC therapy for tissue regeneration/repair, harvest and use of MSCs from adipose tissue and cell-tracking/imaging studies using radionuclides, gene and fluorescent dye-labeled MSCs. SUMMARY: MSCs remain the subject of intense investigation in HCT because of their differentiation potential and immunomodulatory properties. Whereas infusions of autologous, allogeneic and third-party donor MSCs are well tolerated, further research is needed to clarify the optimal methods for harvesting and expansion, optimal timing of administration and efficacy in the setting of HCT. SN - 1531-7048 UR - https://www.unboundmedicine.com/medline/citation/20729733/Emerging_therapeutic_approaches_for_multipotent_mesenchymal_stromal_cells_ L2 - http://dx.doi.org/10.1097/MOH.0b013e32833e5b18 DB - PRIME DP - Unbound Medicine ER -